NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/23/2025
Back to search
Official data from USPTO
ETHYPHARM INNOVATIVE DRUG DELIVERY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
01/23/2025
Trademark type
Combined
Nice classes
5, 42
Filing date
04/21/2011
Registration date
07/24/2012
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/10/2023
Last transaction
01/23/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
FR
Examiner
ANKRAH, NAAKWAMA
Law office
L90
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of the word "Ethypharm" in block letters (the letter "E" is in upper case and the other letters are in lower case), which is plum (Pantone 262 C) in color; under the name "Ethypharm" there is a blue (Pantone Process Blue C) horizontal line to the left and the three words "INNOVATIVE DRUG DELIVERY" in small capital letters to the right, which are plum (Pantone 262 C) in color; to the left of these elements there is an upside-down exclamation mark, which is plum (Pantone 262 C) in color, surrounded by a blue (Pantone Process Blue C) crescent.
Holders and representatives
Holders
ETHYPHARM
Representatives
Thomas W. Brooke Holland & Knight LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of cancercentral nervous system disorderhormonal disordermetabolic disorderimmunologic disordercardiovascular system disorderinfectionpainaddictionophthalmological disordergynecological disorderdermatological disorder; veterinary preparations for the treatment of animal diseasein the nature of cancercentral nervous system disorderhormonal disordermetabolic disorderimmunologic disordercardiovascular system disorderinfectionpainaddictionophthalmological disordergynecological disorderdermatological disorder; sanitary preparations for medical purposesalkaline solutionchloridetensioactive substanceiodine; Dietary food supplementsprotein supplementsinfant formulaspreparation of herbal origin to be used for slimnesscleansing digestioncirculation and relaxationvitaminsmineralslecithinmeal replacement in the form of barsdrinks and capsules; Disinfectants pertaining to the pharmaceutical sectoralkaline solutionchloridetensioactive substanceiodine for hygienic purposes
Class 42
Research and development of new technologies in the medical and pharmaceutical fields; research and development in the field of galenic innovation; research and development in the field of medical solutions; medical and clinical studiesscientific research services for medical purposes; research and development for others in the medical and pharmaceutical fields; engineering in the medical and pharmaceutical fields; chemical research; chemical analysis
Publications
History of USPTO decisions and trademark events.
43 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/27/2024
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
11/05/2023
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
10/16/2023
INPC
INVALIDATION PROCESSED
10/16/2023
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
10/10/2023
C71T
CANCELLED SECTION 71
02/10/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
06/03/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/15/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/12/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/08/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/13/2018
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - MAILED
08/14/2018
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
08/14/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/10/2018
ES75
TEAS SECTION 71 & 15 RECEIVED
07/24/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/19/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/26/2012
FIMP
FINAL DISPOSITION PROCESSED
10/26/2012
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/24/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
07/24/2012
PUBO
PUBLISHED FOR OPPOSITION
05/08/2012
NPUB
NOTICE OF PUBLICATION
04/18/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/04/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/04/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2012
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/13/2012
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/13/2012
CNRT
NON-FINAL ACTION MAILED
01/17/2012
CNRT
NON-FINAL ACTION WRITTEN
01/16/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/16/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/16/2011
ALIE
ASSIGNED TO LIE
12/14/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/08/2011
RFNT
REFUSAL PROCESSED BY IB
08/20/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/03/2011
RFRR
REFUSAL PROCESSED BY MPU
08/03/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/03/2011
CNRT
NON-FINAL ACTION WRITTEN
08/02/2011
DOCK
ASSIGNED TO EXAMINER
08/01/2011
MAFR
APPLICATION FILING RECEIPT MAILED
06/28/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/24/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/23/2011
Continuous trademark protection
Get notified about every new filing that threatens ETHYPHARM INNOVATIVE DRUG DELIVERY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.